Information Provided By: 
Fly News Breaks for November 5, 2019
MYGN
Nov 5, 2019 | 06:25 EDT
Barclays analyst Jack Meehan lowered his price target for Myriad Genetics to $18 from $22 saying the company's Q3 results were "very weak," as new pricing pressure in the core hereditary cancer testing franchise brings coding risks "back to the forefront of the thesis." The analyst expects further pricing risks will represent an overhang for the stock. He keeps an Underweight rating on Myriad Genetics.
News For MYGN From the Last 2 Days
